HeartWare International Inc

HeartWare International — Technical Presentation (November 2009)

26 slides from HeartWare International's technical presentation, Nov 10, 2009

  1. Slide 1: Update on the International Clinical Experience with the HeartWare Ventricular Assist System

    Update on the International Clinical Experience with the HeartWare(r) Ventricular Assist System Martin Strueber, MD Hannover Medical School

  2. Slide 2: European and Australian Experience Overview

    European and Australian Experience Overview More than 100 implants to date Over 60 patients alive on support First human clinical trial (CE Mark) enrolled 50 patients in Europe and Australia - enrollment completed Dec 2008 CE Mark approval received in January 2009 based on data on first 25 patients

  3. Slide 3: First Human Clinical Trial (CE Mark) Overview

    First Human Clinical Trial (CE Mark) Overview First Human Clinical Trial (CE Mark) Overview

  4. Slide 4: Participating Institutions and Physicians

    Participating Institutions and Physicians Centers # Patients Harefield Hospital, UK 3 Asghar Khaghani, Emma Birks Royal Perth Hospital, Australia 8 Gerry O'Driscoll, Rob Larbalestier, Lawrence Dembo St. Vincent's Hospital, Australia 10 Paul Jansz, Philip Spratt Vienna General Hospital, Austria 10 Ge

  5. Slide 5: Patient Demographics (n=50)

    General: Age: 48.5 + 13.6 years BSA: 1.51 to 2.56 m2 (mean 1.97 m2) Weight: 78.4 + 18 kg Patient Demographics (n=50) Gender Distribution Etiology

  6. Slide 6: Preoperative Hemodynamics (n = 50)

    Preoperative Hemodynamics (n = 50) Parameter HeartWare HM II* Cardiac Index (L/min/m2) 1.94 +- 0.54 2.0 +- 0.6 LVEF (%) 18.7 +- 5.9 16.3 +- 5.7 BP Systolic (mmHg) 101.5 +- 13.9 95.8 +- 14.6 BP Diastolic (mmHg) 64.2 +- 10.9 61.7 +- 11.3 Mean BP (mmHg) 76.7 +- 10.6 73 PCWP (mmHg) 23.7 +- 6.5 26.1 +- 7

  7. Slide 7: Duration of Support on HeartWare System (n=50)

    Duration of Support on HeartWare(r) System (n=50) Median duration: 410 days (range: 13-984) Average duration: 406 +- 253 days 28 patients on pump > 1 year; 6 patients > 2 years 55.6 pt years cumulative support 94% of patients discharged Avg. days on pump at transplant: 337 +- 232 days Patients trans

  8. Slide 8: Trial and Device Performance Highlights (n = 50)

    Trial and Device Performance Highlights (n = 50) * Compared admissions during 12 mos pre-implant vs. 12 mos post-implant Two year survival: 84% Six month survival after transplant (n = 20): 95% Survival in 60 and older subgroup (n =14): 93% Successful pericardial placements: 100% Reduction in re-hos

  9. Slide 9: Competing Outcomes (N=50)

    Competing Outcomes (N=50) Months Post Implant % of Patients Data to October 18, 2009

  10. Slide 10: HeartWare Clinical Serious Adverse Events (N=50)

    HeartWare Clinical Serious Adverse Events (N=50) Data to June 2, 2009 Event Number of Patients % of Patients Number of Events Event Rate per Patient Year Infection Local non-device related 7 14% 7 0.15 Sepsis 4 8% 4 0.08 Percutaneous lead infection 8 16% 9 0.19 Pump pocket infection 0 0% 0 0.00 Blee

  11. Slide 11: HeartWare Clinical Serious Adverse Events (N=50), continued

    Event Number of Patients % of Patients Number of Events Event Rate per Patient Year Ventricular Arrhythmias 2 4% 2 0.04 Right Heart Failure 5 10% 5 0.10 Device Replacement 2007 manufacturing defect 2 4% 2 0.04 ingested LV thrombus (d/c anti-platelet therapy) 3 6% 3 0.04 Other obstruction 2 4% 2 0.06

  12. Slide 12: International Trial Summary of Deaths (n = 50)

    International Trial Summary of Deaths (n = 50) Cause Number of Patients POD Died Multi-organ failure 4 15, 73, 103 and 195 Sepsis 2 13, 84 Hemorrhagic stroke 2 203 and 503

  13. Slide 13: Hemodynamic Changes Post HVAD Implant (n = 50)

    Hemodynamic Changes Post HVAD(tm) Implant (n = 50) Significant improvements pre-implant vs. post implant hemodynamic parameters p-value 0.005 p-value 0.001 p-value 0.001

  14. Slide 14: International Trial Quality of Life Scores

    International Trial Quality of Life Scores Kansas City Cardiomyopathy Questionnaire Quality of Life Time

  15. Slide 15: International Trial Neurocognitive Evaluation (n = 44)

    International Trial Neurocognitive Evaluation (n = 44)

  16. Slide 16: Conclusions from HeartWare International Trial

    Conclusions from HeartWare International Trial Promising results with 90% survival at 180 days in first human study Successful implant in the pericardial space without surgical pump pocket Patient implant days unusually long for an LVAD trial without adversely impacting AE rates Excellent survival p

  17. Slide 17: Disclaimer

    Disclaimer The HeartWare(r) Ventricular Assist System is the subject of an investigational clinical trial in the United States for a bridge-to-transplant indication. Pursuant to United States federal law, the HeartWare(r) Ventricular Assist System is restricted solely to investigational use in the U

  18. Slide 18: Hannover Medical School Experience with the HeartWare System

    Hannover Medical School Experience with the HeartWare(r) System PROF. MARTIN STRUEBER - HANNOVER MEDICAL SCHOOL, HANNOVER

  19. Slide 19: The Hannover Medical School Experience

    The Hannover Medical School Experience 41 implants (47% clinical / 53% commercial) 2 myocardial recovery (POD 534 and POD 584) 2 patients transplanted (POD 638 and POD 770) Total duration of pump support: 28.8 years Results to date indicate: HVAD(tm) Pump is versatile and provides options for placem

  20. Slide 20: HVAD Pump Allows for Procedural Versatility

    HVAD(tm) Pump Allows for Procedural Versatility Pericardial placement straightforward Also enables rescue of other VAD patients (2) Thoracotomy placement (2) Option for patients who cannot tolerate sternotomy Note: makes cleaning out Ventricle pre-implant more challenging BiVAD placement (1)

  21. Slide 21: Hannover HVAD Pump Surgical Implant

    Hannover HVAD(tm) Pump Surgical Implant

  22. Slide 22: Hannover Implantation Via Lateral Thoracotomy

    Hannover Implantation Via Lateral Thoracotomy (off pump) (off pump) (off pump) (off pump)

  23. Slide 23: HVAD Pump as BiVAD at Hannover

    HVAD(tm) Pump as BiVAD at Hannover

  24. Slide 24: Hannover - HVAD Pump Ease of Use

    Simplified surgical procedure All 100% pericardial placements CPB time: 36-125 min in CE Mark Trial Minimal blood products required...often none Multiple steps for other systems eliminated in HVAD(tm) implant When required, sewing ring facilitates straightforward pump exchanges (1X in post CE patien

  25. Slide 25: Hannover - HVAD Pump Reliability & Durability

    Hannover - HVAD(tm) Pump Reliability & Durability Hannover experience in 50 patient CE Mark Study 19 implants Average time on pump: 470 + 231 days Longest patient on pump: 770 days Pump failures: 0 Driveline failures: 0 Controller failures: 0

  26. Slide 26: Next? Confirm Trial Results = Real World REVoLVE Registry

    Next? Confirm Trial Results = Real World REVoLVE Registry Multi-center international registry to study HeartWare(r) System in "the real world" Unrestricted grant by HeartWare Data management by Hannover Medical School International centers invited to participate Presentation of first 99 Internationa

HeartWare International — Technical Presentation (November 2009) on 6ix